The partial 5-HT1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy
KL Eskow, V Gupta, S Alam, JY Park… - … Biochemistry and Behavior, 2007 - Elsevier
Dopamine (DA) replacement therapy with l-DOPA remains the standard pharmacotherapy
for Parkinson's disease (PD). Unfortunately, chronic l-DOPA treatment is accompanied by
development of motor fluctuations and l-DOPA-induced dyskinesia (LID). While serotonin (5-
HT) 1A agonists acutely reduce these complications, their prophylactic and long-term effects
are not well-delineated. To test this, male Sprague–Dawley rats received unilateral 6-
hydroxydopamine (6-OHDA) lesions. In experiment 1, l-DOPA-primed rats were pre-treated …
for Parkinson's disease (PD). Unfortunately, chronic l-DOPA treatment is accompanied by
development of motor fluctuations and l-DOPA-induced dyskinesia (LID). While serotonin (5-
HT) 1A agonists acutely reduce these complications, their prophylactic and long-term effects
are not well-delineated. To test this, male Sprague–Dawley rats received unilateral 6-
hydroxydopamine (6-OHDA) lesions. In experiment 1, l-DOPA-primed rats were pre-treated …
